as 12-24-2024 1:39pm EST
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world.
Founded: | 1987 | Country: | United Kingdom |
Employees: | N/A | City: | LONDON |
Market Cap: | 2.8B | IPO Year: | 1993 |
Target Price: | $67.14 | AVG Volume (30 days): | 564.5K |
Analyst Decision: | Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.43 | EPS Growth: | 759.09 |
52 Week Low/High: | $43.15 - $64.48 | Next Earning Date: | 02-19-2025 |
Revenue: | $1,241,739,000 | Revenue Growth: | 11.04% |
Revenue Growth (this year): | 10.1% | Revenue Growth (next year): | 5.43% |
LIVN Breaking Stock News: Dive into LIVN Ticker-Specific Updates for Smart Investing
Business Wire
6 days ago
Argus Research
7 days ago
Argus Research
14 days ago
Business Wire
19 days ago
Argus Research
21 days ago
Simply Wall St.
a month ago
Zacks
a month ago
Argus Research
a month ago
The information presented on this page, "LIVN LivaNova PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.